Our biology-led in silico laboratory enables rapid hypothesis generation and phenotypic screening of millions of compounds and/or targets.

At e-therapeutics, our team of multi-disciplinary experts builds computational models of biological functions to transform the search for new medicines, interventions, mechanisms and genetic support.

Novel targets can be identified, prioritised and assessed with greater confidence in the biological context. Harnessing internal target gene discoveries, we are currently building an in-house pipeline of RNAi-based medicines, using its proprietary GalNAc-siRNA technology.

Cost of developing a drug 

$2.6B

Late-stage failures could be minimised with better drug discovery 

gettyimages-1155390118_555x474.jpg

Unique convergence of two cutting-edge technologies

Applying computational power to the design of better RNAi medicines

Item 1

>15M

compounds

Item 2

>300M

datapoints

Item 3

>70

data sources

Item 4

100–1,000x

hit rates in small molecules

Item 1

>15M

compounds

Item 2

>300M

datapoints

Item 3

>70

data sources

Item 4

100–1,000x

hit rates in small molecules

  1. Convergence of cutting-edge technologies: AI and RNAi
  2. Proprietary GalNAc-siRNA genetic medicine platform technology 
  3. Third-party and in-house experimental validation of our computational platform
  4. Emerging therapeutic pipeline, leveraging novel target identification capabilities